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Introduction
This capstone report includes three manuscripts, focused on adolescents in regards to
prescribing practices, risk behaviors correlated with depressive symptoms, and risk behavior in a
primary health clinic. The first manuscript presents a critical analysis of prescribing trends of
antipsychotic medications in youth, especially for behavior control. The second manuscript
presents a literature review pertaining to adolescent risk behaviors that may contribute to
depression based upon the Centers for Disease Control’s (2013) screening recommendations.
Based in part upon the literature from these first two manuscripts, a descriptive study was
performed which examined risk behavior screening practices and the patterns of behaviors and
risk level among patients treated at an adolescent health clinic in the southeastern United States
using the PARS screening instrument. Finally, the third manuscript presents results from this
study and implications for practice improvement services for depression screening in this at-risk
population.
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Antipsychotic Use in Children and Adolescents: Analysis of Trends Versus Evidence
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Introduction
Antipsychotic medications were developed in the 1950s to treat symptoms associated
with psychotic disorders, such as schizophrenia. In the last few decades, these medications have
also been approved by the Food and Drug Administration (FDA) to treat other psychiatric
disorders in adults such as bipolar disorder, schizoaffective disorder, and as an adjunct
medication in treatment resistant major depressive disorder (Elsevier, Gold Standard, Inc., 2013).
The older medications, known as typical or first-generation antipsychotics (FGAs), have been
effective in treating positive symptoms of schizophrenia such as hallucinations, delusions,
aggression, and hostility. Unfortunately, the therapeutic effects of these medications have been
inadequate in the treatment of negative symptoms of schizophrenia such as apathy, social
isolation and withdrawal, and lack of motivation. In addition, these medications have a high rate
of extrapyramidal side (EPS) effects that include dystonic reactions (involuntary spasm or
jerking of muscles in the body), akasthisia (the inability to sit still due to involuntary movements,
especially in the limbs), drug-induced Parkinsonism, and tardive dyskinesia (involuntary rolling
of the tongue and twitching of the face, trunk, and/or limbs).
Atypical, or second-generation antipsychotics (SGAs) were introduced in the 1980s and
are similar to the FGAs in reducing psychotic symptoms in patients with psychosis but with
fewer and less severe side effects than the FGAs (Lieberman et al., 2005). Although they have
proven to be as effective as FGAs in treating the symptoms of psychosis, the atypical
antipsychotics have shown to have a higher incidence of metabolic adverse effects and weight
gain.
Even with this increased risk for metabolic adverse effects, there are, however, specific
SGAs that have been approved for use in the pediatric population for certain disorders, including
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irritability with autistic disorders, schizophrenia, and bipolar I disorder with mixed or manic
episodes. However, many children are also treated with SGAs for psychiatric illnesses that have
no FDA approval; for example, Doey, Handelman, Seabrook and Steele (2007) reported that
impulsivity, aggression, obsessive-compulsive disorder, and insomnia were frequently treated
off-label with SGAs.
The purpose of this literature review is to identify trends associated with SGA use within
the population under the age of 18, as well as prescriber practices, psychiatric conditions
associated with SGA use, and safety issues with antipsychotic medication in the pediatric
population, specifically in adolescence.
Methods
Search Methods
Literature from 2006 to 2013 was reviewed from searches in PubMed, CINAHL,
MEDLINE, and PsychLit with the following search terms: antipsychotics, adolescents, children,
youth, English language, published in the last decade, guidelines, prescribing, trends, mental
illness, psychosis, aggression, schizophrenia, mood, bipolar, Medicaid, insurance. Studies were
limited to those that had included primarily second-generation antipsychotic medication use in
persons 18 and under without regard to any specific diagnoses, treatment setting, and without a
focus on specific racial/ethnic group or gender.
Search Results
The above databases were searched for abstracts with the key word search terms. The
search yielded 17 articles. Ten of these articles were chosen based upon the quality of the
study/paper and the authoritative source and were made up of systematic literature reviews,
practice parameters, retrospective trend analyses, and cross-sectional studies.
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Findings
All of the 10 studies included in this literature review examined the potential for intrinsic
safety issues associated with the use of antipsychotic medications in young people. Two studies
reviewed the prescribing trends in privately insured children, three studies primarily reviewed
trends in publicly insured children and the possible explanations for this development, two were
primarily to generate practice parameters, two specifically studied the adverse effects of these
medications in young people (although all studies noted this information but in much less detail)
and one study reviewed much of this information from the other studies and included more
recent data of use across 11 health maintenance organizations. As the availability of inpatient
treatment for psychiatric illnesses have substantially decreased, almost all of the studies
reviewed were based in a physician office setting: primary care, family practice, or psychiatry.
The patterns of antipsychotic medication prescribing and use are of great importance to
professionals who treat the pediatric population; the consequences of not following the best
practice guidelines fall mainly on the child, no matter what physician specialty is prescribing the
medication. Rettew et al. (2015) found evidence that antipsychotic medications were not
necessarily being handed out to treat insignificant behavioral problems, as has been postulated in
some of the research, but they found several areas where providers were not following best
practice recommendations. One particular discovery they found was that antipsychotic
medications were being prescribed following the guidelines only about half of the time and only
followed FDA-approved conditions about one-fourth of the time.
Insurance influence on prescribing trends
The frequency of psychotropic medication prescribing has increased in the last 2 decades,
particularly with antipsychotic medications. According to Zito, Burcu, Ibe, Safer, and Magder
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(2013), antipsychotic use in youth within the Medicaid population has dramatically risen in
conjunction with the overall increase found in adolescents. Many reasons have been
hypothesized for the increase in rates, especially in the public insurance sector. For example,
higher poverty rates among those insured by Medicaid have been associated with reduced access
to comprehensive services; this has led the demand for more rapid symptom stabilization for
behavioral problems in children. In addition, a greater frequency of psychiatric conditions and
behavior disorders are diagnosed in children who are insured by Medicaid, decreased provider
reimbursement for thorough and time consuming mental health assessments, and pressure from
stressed families may make antipsychotic medications a more attractive option for treatment
(Zito, Burcu, Ibe, Safer, & Magder, 2013; Pathak, West, Martin, Helm, & Henderson, 2010;
Harrison, Cluxton-Keller, & Gross, 2012).
Changes in prescribing patterns can be attributed in part to: scientific advances in
antipsychotic medications from FGAs to SGAs (each with a different side effect profile); FDA
approval for certain SGAs in the diagnosis of bipolar disorder, schizophrenia, and autism
spectrum disorder in young people; an increase in the Hispanic population; and increased
coverage for the children’s insurance program in each of the state’s Children’s Health Insurance
Program (SCHIP). For example, Zito et al. (2013) identified the predominant clinical and
demographic characteristics of youth who had the highest rates of antipsychotic use. These
included the youth who were more family income level eligible (qualified for state and federal
assistance like SCHIP) over youth who were considered vulnerable (who were in the foster care
system or received Supplemental Security Income [SSI] for a disability). In addition, very young
children (ages 2 to 4 years, even though no FDA approved disorders for the use of SGAs exist
for this age group) showed an increase in use similar to youth ages 10 to 17, and the greatest
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proportionate youth increases were in the Hispanic population. Externalizing behavior disorders
were more frequently treated with antipsychotic medications compared to diagnoses of
schizophrenia, psychosis, or other severe conditions of development.
The use of antipsychotics for treatment of behavioral issues greatly exceeded that of
treatment for psychotic disorders. Pathak, West, Martin, Helm, and Henderson (2010) came to
similar conclusions in their study. In looking at the Arkansas Medicaid program during the years
2001-2005, they found that the number of children treated for the first time with SGAs increased
from 1,482 to 3,110 during the duration under study. Overall, almost half of the youth who
received a SGA in these studies had no supporting diagnosis to justify the use of these
medications; over half of this number of antipsychotic use was for attention-deficit hyperactivity
disorder (ADHD)—a condition that has not been approved by the FDA for treatment with
antipsychotic medications (U.S. Department of Health and Human Services, Agency for
Healthcare Research and Quality [AHRQ], 2013). Interestingly, the majority of providers who
prescribe antipsychotic medications to pediatric patients for non-FDA approved off-label use in
the outpatient setting are psychiatrists (64.1%) followed by pediatricians (9.5%), nurse
practitioners (7.7%), unspecified (6.3%), general practice/family medicine (4.9%), and all others
(7.4%) (Chai, Mehta, Moeny, & Governale, 2013).
In office-based settings, Olfson, Blanco, Liu, Moreno, and Gonzalo in 2006 found that
antipsychotic medications were prescribed more often for young people on Medicaid more so
over young people covered under private insurance, possibly due to the effect of higher mental
health disabilities and foster children being insured through Medicaid (Fortuna, Fulwiler, Stone,
Smith, & Biebel, 2008). But a later study by Olfson, Blanco, Liu, Wang, and Correll (2012)
noted continued increases of antipsychotic use in youth across the board, regardless of the pay
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source (although publicly insured youth continued to have the most antipsychotic medication
management visits); males diagnosed with a disruptive behavior disorder had a majority of these
visits. Notably, for the years 2005-2009, the authors found the bulk of the antipsychotic
medications prescribed were for a disruptive behavior disorder diagnosis; the FDA has not
approved treatment for these disorders with an antipsychotic medication. Likewise, they found
that a diagnosis of bipolar disorder in youth was a common reason for prescribing these
medications, even more so than for adults, yet diagnosing bipolar disorder in youth is not an
accurate science.
These trends are not relegated solely to the publicly insured youth. In a study of privately
insured, very young children (ages 2 through 5) during the years 1999-2001 and 2007, Olfson,
Crystal, Huang, and Gerhard (2010) noted that the overall amount of psychotropic medications
prescribed to this age group did not differ much in the two time periods under study, but the
types of psychotropic medications filled differed significantly with the greatest increase in
antipsychotic medications. Males were more commonly treated with antipsychotic medications,
and the most common diagnosis for antipsychotic use was bipolar disorder (as was discovered by
the authors again at a later date). Olfson et al.’s (2010) final assessment concluded that the
majority of these very young privately insured children who were treated with an antipsychotic
medication did not receive the most rudimentary mental health services during this time period
such as a thorough mental health assessment, any type of psychotherapy, or a consult with a
psychiatrist. This may be due to lack of treatment access. Repeatedly, these studies noted that
aggressive behaviors seem to be the end point that antipsychotic medications are being targeted
for in off-label use among patients under 18 years of age.
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Conditions treated with antipsychotics
Olfson et al. (2012) noted that a possible explanation for the increase in antipsychotic
prescribing in younger people was the FDA approval for certain medications to treat the
following conditions in youth: bipolar disorder, schizophrenia, and irritability associated with an
autistic spectrum disorder as well as certain published clinical trials and practice guidelines for
use in unapproved conditions. Researchers examining the use of antipsychotics in children with
these approved diagnoses found that improvements in the symptoms of irritability, self-injurious
behavior, aggression, and tantrums associated with Autism Spectrum Disorder (ASD) are
significant, especially with the SGA risperidone (Aman et al., 2008; Pandina, Bossie, Youssef,
Zhu, & Dunbar, 2007; Harrison, Cluxton-Keller, & Gross, 2011). In addition, Risperidone is
approved treatment for schizophrenia and bipolar disorders in adolescents; aripiprazole was later
approved for treatment of schizophrenia and bipolar I disorder in children ages 10-17 (Pathak et
al., 2008; Crowley et al., 2014).
Bipolar disorder and autism spectrum disorder diagnoses have increased markedly in
youth over the past decade, and along with the lower EPS risks with SGAs over FGAs, FDA
approval for use with certain conditions, and the overall level of increased prescriber comfort
with these medications probably account for some of the increases in antipsychotic use. Pathak
et al. (2008) also brought up other plausible reasons for the upsurge: the rise in behavioral
managed care alongside strictly limited reimbursement for psychotherapy leading toward a
greater use of pharmacological interventions; mental health treatment stigma may be to a lesser
degree; and a greater acceptance of psychotropic medications in the general population as
pharmaceutical manufacturers use intense marketing to consumers. Harrison, Cluxton-Keller,
and Gross (2011) and James (2010) proposed similar possible reasons for the increased
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antipsychotic use in children, especially for off-label treatment. These include the acceptance of
psychotropic medication use in the pediatric population, limited access and inadequate supply of
mental health professionals to treat this population, demand for rapid treatment that is affordable
(unlike therapy which can take multiple visits and cost more than what a family can afford),
limited provider time and reimbursement issues for treating behavioral problems (without
medications), and the options for treatment in vulnerable populations that have limited resources
and access to care.
The American Academy of Child and Adolescent Psychiatry (AACAP, 2011) found that
antipsychotic prescribing has dramatically increased in the last 17 years, especially for mood
disorders and by non-psychiatrist physicians, and they noted off –label use for antipsychotics
(particularly SGAs) have been a major influence on the prescribing of these medications to
youth, even without FDA approval. Currently, the FDA approved conditions for antipsychotic
use in minors are schizophrenia, bipolar I disorder (manic or mixed), and irritability found with
autism; the medications approved for these conditions are: aripiprazole, olanzapine,
paliperidone, quetiapine, and risperidone (FDA, 2013). Of these, risperidone and aripiprazole
are the only medications approved for use in ASD in youth ages 5-11. The Centers for Medicare
and Medicaid Services (CMS) report, “More than three-fourths of youths on Medicaid are taking
one of these [atypical antipsychotics] medications for an indication that is not FDA approved”
(U.S. Department of Health and Human Services, AHRQ, CMS, pg. 2, 2013). Supporting the
CMS report, Pathak et al. found in their study, 41.3% of new users of antipsychotic medications
(SGAs) under the age of 18 were for a diagnosis not approved by the FDA; Penfold et al. (2013)
also discovered that the majority of children on antipsychotic medications did not have one of
the approved conditions for use. Interestingly, in the European Union countries aripiprazole is
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the only approved antipsychotic medication for youth ages 15-17 who have schizophrenia,
although a few countries also have the approval for use of risperidone for severe disruptive
disorders in children and adolescents (Findling et al., 2008). The use of these medications is not
without great risks to the child such as weight gain, cardiometabolic effects, and the unknown
long-term effects of use on a child’s growth and brain development.
Safety
Antipsychotic medications, especially the newer SGAs, have unfortunately contributed to
the pervasiveness of obesity in the medicated schizophrenic population; current estimates range
from 40 to 60% versus 30% of the general adult population (Sokal et al., 2004). In addition, use
of the SGAs increases the risk of acquiring or exacerbating type II diabetes, especially in female
youth (Nielsen et al., 2014; Cohen, Bonnot, Bodeau, et al., 2012). SGAs can cause a substantial
amount of weight gain as well as an increased risk for metabolic changes; each medication has
varied levels of these effects. Aripiprazole has a higher percentage of EPS related effects in
youth over adults and is not indicated as a monotherapy treatment for major depressive disorder
(Nielsen et al., 2014). In addition, treatment with aripiprazole is associated with increased
suicidal ideation among people under the age of 24 (U.S. Department of Health and Human
Services, AHRQ, CMS, 2013). Many adverse effects have been observed with the use of SGAs
among the child and adolescent population including weight gain and hyperlipidemia in
adolescents taking olanzapine, increased metabolic effects with paliperidone, blood pressure
increases associated with quetiapine, and weight gain with risperidone (Panagiotopoulos,
Ronsley, Elbe, Davidson, & Smith, 2010; Correll, & Kratochvil, 2011; Cohen, Bonnot, &
Bodeau, 2012).
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De Hert, Dobbelaer, Sheridan, Cohen, and Correll (2011) conducted a systematic review
of randomized controlled trials (RCT) with SGAs to investigate the adverse metabolic effects of
these medications in the under age 18 population. They reviewed 31 RCTs that included 3,595
patients in the pediatric population. This review indicated that youth under age 18 had a much
greater risk of hyperprolactinemia, weight gain, and other metabolic disturbances resulting from
treatment with SGAs. In their study, ziprasidone had the lowest risk for weight gain;
aripiprazole, quetiapine and risperidone showed moderate amounts of weight gain; and
olanzapine showed the most weight gain effects. This weight gain also tended to be in younger
patients with ASD who had no prior experience with SGA treatment. Seida et al. (2011)
conducted an extensive systematic literature review to investigate safety and efficacy of FGAs
and SGAs in youth under 24 years of age. They too found that olanzapine caused more
dyslipidemia and weight gain, but fewer prolactin-related events than risperidone; olanzapine
caused more weight gain than quetiapine.
Children may suffer different and/or more serious side effects than adults from taking
antipsychotic medications. Different rates of absorption and distribution within the tissues and
cells exist due to the relative mass of the liver and kidneys (when adjusted for weight), and
children’s bodies have more water and less fat compared to adults. This could potentially be a
contributing factor for higher risk of metabolic adverse effects among youth treated with SGAs
compared to those experienced by adults. It is imperative that safe-dose range limits are
established and disseminated in practice guidelines. This prompts and supports the need for
baseline measures recorded for every child who is prescribed antipsychotic medications and
continued monitoring for the duration of treatment.
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Discussion
The objective of this literature review was to identify trends in the use of antipsychotic
medications in children and adolescents. Based upon the literature critically appraised for this
paper, findings indicate an increasing trend in the prescribing of antipsychotic medications in
young people (specifically SGAs) by many providers, some not specialized in psychiatry or
mental health. This clinical problem is heightened when considering that the FDA has not
approved the use of these medications for several of these illnesses. Disruptive, aggressive,
oppositional, and other behaviors that do not respond to parental controls appear to be a common
reason for providers choosing this route of treatment. A small number of SGAs are approved to
treat some psychiatric conditions in young children and adolescents, but most of the children on
the medications in the reviewed studies did not have one of the approved diagnoses. The main
concern for using these medications in young people is their increased risk of experiencing
adverse side effects such as weight gain and/or metabolic changes; these could have devastating
consequences for health into adulthood. A major concern is that these are just the adverse effects
that have been studied—no long-term data exists for the effect these medications could have on
growth and brain development.
Implications
Important concerns that need to be addressed in future research include strategies to
improve access to psychosocial treatments with qualified providers, the urgent need for high
quality studies to determine the efficacy and safety of off label use of antipsychotic medications,
and standardization for outcome measurements for the purpose of ascertaining clinically
important outcomes and the degree to which changes in symptoms and functioning are
significant. Telemedicine psychiatry may be a viable option to improve accessibility in areas
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where pediatric psychiatrists or collaborative physicians are limited. Additional studies are
needed to examine the dose-related effects of the different medications on weight gain, metabolic
adverse effects (dyslipidemia, glucose, prolactin, blood pressure, liver function) in addition to
health-related quality of life, social functioning, and the effects on the involvement in the legal
system (Harrison, Cluxton-Keller, & Gross, 2012; Seida, et al., 2012; De Hert, et al., 2011). A
2012 AHRQ study of FGAs and SGAs in children and adolescents concluded that further
research was needed the most in three categories including long-term outcomes for effectiveness,
long-term risks of medication use, and differences in efficacy, effectiveness, or incidence of
adverse effects in the various subpopulations of young people who take antipsychotic
medications.
Further Implications
In addition to the need for increased standardization of off-label use of antipsychotic
medications and increasing access to other psychotherapeutic modalities of treatment, other
therapeutic parameters must be investigated. Some of the areas of treatment that need further
study include determining the numbers of very young children unnecessarily diagnosed with
psychiatric disorders, such as bipolar, and needlessly prescribed antipsychotic medications and
safety issues among children prescribed several psychotropic medications simultaneously.
Comprehensive psychiatric assessment must be performed before starting any psychotropic
medication in a young person in order to arrive at a precise decision for the best treatment.
For the child’s safety, non-pharmacological interventions should always be utilized as a
first line of treatment including such interventions as parental skills training and support when
indicated. Many behavioral problems in children are often strongly associated with problematic
family relationships and stressful home environments; medications cannot fix these core
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problems. Adequate provider training for use of these medications should also be a priority. As
a best practice, primary care providers should collaborate with psychiatrists or psychiatric nurse
practitioners before prescribing psychotropic medications. However, the collaboration between
primary care and mental health professionals rarely occurs (Wissow et al., 2013). To address
this treatment barrier, some states have created monitoring oversight for collaboration between
pediatricians, primary care providers, and specialists in child psychiatry (Medicaid Medical
Directors Learning Network & Rutgers Center for Education and Research on Mental Health
Therapeutics, 2010). Some states have started implementing strict monitoring for the use of
psychotropic medications in children, especially antipsychotics, in the Medicaid population
(Colorado Department of Health Care Policy and Financing, Colorado Department of Human
Services, 2013). These programs are a step forward in ensuring the safety of our children.
Conclusion
The trend in the use of antipsychotic medication in young people has increased
dramatically over the last 15 years, many prescribing practices without the benefit of psychiatric
specialty collaboration or for FDA-approved conditions. The publicly insured youth have the
highest use of these medications but increases in privately insured have also been noted.
Antipsychotic medication can have serious adverse effects on youth; more so than on adults, and
this outcome can be found in most of the literature published regarding antipsychotic use among
children. However, these studies are limited, and the long-term effects on children have not been
fully examined.
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Abstract
Title: Evaluating risk-behavior screening for identifying adolescent depression: a literature
review
Aim: The purpose of this literature review is to analyze and present recommendations regarding
the identification of adolescent depression from the 2013 Centers for Disease Control
recommended behavior domains on risk screening instruments.
Background: Over 2 million youth report a major depressive episode yet 60% of these youth
did not receive any kind of treatment. Depression is consistently the highest risk factor for
adolescent suicide. Depression screening has been recommended for primary care and riskbehavior instruments are commonly used. Domains other than the “mental health” domains on
these instruments may indicate depression as well and need to be taken into consideration when
assessing for adolescent depression in primary care.
Design: Integrative literature review
Method: MEDLINE, The Cochrane Library, PubMed, PsychINFO, and CINAHL databases
were searched for studies from search terms: adolescents, high-risk behavior, youth, screening,
depression, correlates, primary care, smoking, substance use, predictors and depression,
domains, assessment, behavior and emotional disorders, mental health, teenagers. The literature
on this topic is limited. Most of the 8 studies narrowed down for inclusion in this review were of
a cross-sectional design.
Results: Identified factors potentially associated with adolescent depression include cigarette
smoking, the environment surrounding school/academics, stress associated with worries about
the family stability, gender differences on prevalence of depression, and attitude/perceptions
from a negative cognition.
Implications: Although few high quality studies were available, the identified factors noted are
included in the domains of risk-behavior screening instruments. These should be taken into
consideration as possible indicators for the presence of depression when triggered and the youth
should be assessed for need of further evaluation.
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Depressive symptoms were reported by 2.2 million youth ages 12-17 in the United States
in 2012; sixty percent did not receive any kind of treatment (Substance Abuse Mental Health
Services Administration [SAMHSA], 2012). Depression is consistently the most common risk
factor for adolescent suicide, which has been the 3rd leading cause of death for teens for many
years (Gould, Shaffer, & Greenberg, 2003; the Centers for Disease Control [CDC], 2012). In
2009 the US Preventive Services Task Force (USPSTF) recommended screening for adolescent
depression in primary care, but levels of depression screening in primary care have been
suboptimal (Irwin, Adams, Park, & Newacheck, 2009).
Risk behavior assessment tools have also been recommended to screen for depression in
adolescents in primary care (CDC, 2013; The National Institute of Health Care Management
[NIHCM], 2010). Several screening tools are available for clinicians in the assessment of risk
factors associated with depression in youth. For example, Salerno and Barnhart (2014) evaluated
the 21-item Rapid Assessment for Adolescent Preventive Services (RAAPS) for utility in
identifying adolescent depression in primary care services compared with the Patient Health
Questionnaire-Adolescent (PHQ-9), considered the “gold standard” for depression screening in
primary care; the RAAPS was shown to be a valid and reliable measure of adolescent depression
and has been recommended by the USPSTF (2009). However, the currently available tools have
shown wide variations in the inclusion of relevant assessment domains that could alert the
clinician to the need for further evaluation and referral for depression, and provider interpretation
on the need for further evaluation can vary depending on the screening tool used in the
assessment. The purpose of this literature review is to analyze, identify, and propose alternative
behavior characteristics to assess for adolescent depression from the CDC (2013) recommended
behavior domains on risk screening instruments.
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Background
The goal for adolescent depression screening is to increase rates of identification of
depression and implement early interventions such as referral, more in-depth screening,
treatment, and follow-up. Ultimately, earlier interventions may decrease the risk of negative life
outcomes that can take place when depression is not identified and treated (USPSTF, 2009).
Depression screening has been shown to be effective at identifying depression in adolescents
leading the USPSTF to make several screening recommendations in 2009. However, these tools
are specific to depression and as such, are infrequently offered to adolescent patients in the
primary care setting because providers report time and training as barriers in their screening
practices (Irwin et al., 2009; Olson et al., 2001).
Risk behavior screening may be a more practical approach and can yield much
information about the overall health of an adolescent. The CDC (2013) has identified several
risk behaviors for morbidity and mortality in adolescents and recommended evidence-based risk
screening for these behaviors, or domains, in the primary care setting. These risk behaviors
include unintentional injuries; presence of violence/aggression; mental health issues; tobacco
use; use of alcohol and other drugs; sexual behaviors contributing to unintended pregnancy,
sexually transmitted infections (STIs) and HIV; unhealthy dietary behaviors and lack of physical
activity. A number of protective factors have also been identified such as social support, life
goals, and/or a trusting relationship with an adult (Michigan Quality Improvement Consortium
[MQIC], 2013). Engagement in risky behaviors can greatly affect the present and future mental
health of an adolescent, and these behaviors are evident in adolescents with depressive symptoms
much more than those without depressive symptoms thus raising their risk for further mental
illness (Institute of Medicine [IOM] and National Research Council Committee on the Science of
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Adolescence, 2011; Waller et al., 2006). Since 2013, the MQIC, along with the Agency for
Healthcare Research and Quality (AHRQ), have recommended that adolescent risk behavior
screening should be performed at least annually with a validated screening tool. There is a lack
of systematic evidence-based guidelines for the identification of potential depression as
determined via a risk assessment-screening instrument. However, evidence-based studies have
identified risk behaviors associated with an increased risk for depression (IOM and National
Research Council Committee on the Science of Adolescence, 2011; Forman & Davies, 2003;
Haarasilta, Marttunen, Kaprio, & Aro, 2004; Richmond, Mermelstein, & Metzer, 2012), but
limited data exist to connect those known risk factors with their correlated domains on a risk
screening instrument.
Methods
Search Methods
The MEDLINE, Cochrane Library, PubMed, PsychINFO, and CINAHL databases were
searched for studies using the following search terms: adolescents, youth, high-risk behavior,
screening, depression, correlates, primary care, smoking, substance use, predictors and
depression, domains, assessment, behavior and emotional disorders, and mental health. Most
studies were of a cross-sectional design as the literature was limited.
Inclusion criteria for the studies in this review were: (a.) males, females, or mixed gender
between the ages of 12-21 years; (b.) all races and ethnicities; studies written in the English
language; (c.) settings to include primary care, pediatrician offices, schools, or outpatient
settings; (d.) the use of screening/assessment tools for their study with measures to include
depression/depressive symptoms along with other areas of behavior and/or emotion; (e.) outcome
of study is associated with depression (connection or note to other domain areas); and (f.) studies
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within the last decade. Included studies did not require a formal diagnosis of depression among
the participants, but they did need to identify the presence of depressive symptoms. Exclusion
criteria included (a.) a focus on participants who dropped out of school, (b.) juveniles in the
justice system, (c.) incarcerated youth, (d.) adolescents in substance abuse treatment, and (e.)
institutionalized youth. Studies that included only college attendees, focused on a specific
racial/ethnic group, or concerned primarily with adult outcomes were also excluded.
Search Results
The databases were searched for abstracts meeting the key word search terms. Initially,
38 studies met the inclusion criteria of which 22 were eliminated with the exclusion criteria.
Sixteen studies remained. No randomized controlled trial (RCT) studies met the inclusion
criteria for this literature review.
Findings
Of the 16 studies included in this literature review several evaluated early identification
of potential depression in adolescence in primary care and adolescent risk screenings/tools
(Salerno and Barnhart, 2014; NIHCM, 2010; American College of Preventive Medicine
[ACPM], 2011). Three studies reviewed the relevance of the school environment on behaviors
contributing to adolescent depression (Haarasilta et al., 2004; Richmond, Mermelstein, &
Metzger, 2012; Respress, Morris, Lewin, & Francis, 2013), two studies examined the
interpersonal relationship factors (Yaroslavsky, Pettit, Lewinsohm, Seeley, & Roberts, 2013;
Dumont & Olson, 2012), three studies considered the characteristics of the individual in relation
to depression (Dumont & Olson, 2012; Rood, Roelofs, Bogels, & Meesters, 2012; Rockhill, et
al., 2013), and several looked at gender as a potential mediating factor and the specific behaviors
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related to gender (Seeley, Stice, & Rohde, 2009; Waller et al., 2006; Rubin, Gold, & Primack,
2009).
Several themes emerged from this review, and some aspects of one theme may converge
with another theme. The predominant themes included specific environmental influences
potentially influencing the development of depression, interpersonal relationships and individual
characteristics and vulnerability for depression; the role of gender and gender specific behaviors
also emerged as a theme suggesting increased risk for depression. Most of the studies mentioned
differences in presenting complaints and/or symptoms between adolescents and adults. The
themes are of great importance in linking various risk behaviors to potential adolescent
depression especially for the behaviors unknowingly connected to depression.
Influence of peers/school environment
Healthcare providers have a widespread knowledge base on the risk factors for
depression in adolescents, mainly due to treatment guidelines developed by various expert
organizations (IOM and National Research Council Committee on the Science of Adolescence,
2011; NIHCM, 2010; USPSTF, 2009; ACPM, 2011). The evidence base indicates that a history
of depression, mental or medical comorbidity, substance use, history of trauma, and many other
factors increase the risk of developing mental health issues (IOM and National Research Council
Committee on the Science of Adolescence, 2011). Other more subtle factors may also influence
the development or presence of depression. For example, peers and friends at school are
extremely important to an adolescent for a multitude of reasons. Adolescence is a vulnerable
time period in a child’s social development, and peer rejection may lead to gravitation towards
deviant peers to decrease a sense of isolation. The choice of peers can have a "domino effect"
for behaviors that are associated with depression such as drug use, delinquency, and other high-
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risk behaviors (Haarasilta et al., 2004; Richmond, Mermelstein, & Metzger, 2012; Respress et
al., 2013).
The influence of negative peer interactions greatly increases an adolescent’s risk for
depression over time. Richmond, Mermelstein, and Metzer (2012) conducted a 24-month
longitudinal study to examine the risk and protective factors associated with deviant and nondeviant peers in high school students. Deviant behaviors are defined as behaviors being outside
of the accepted cultural norm for a group or society such as drug use, promiscuity, and
delinquency for example [Merriam-Webster, 2015]. Richmond and colleagues found that
protective factors of non-deviant friendships decreased the risks associated with the influence of
deviant peers with regards to cigarette smoking and alcohol use, but had no reduction effect on
depressive symptoms. The findings suggest a negative impact associated with peers, specifically
on depressive symptoms. Negative peer interactions are noted to be the most consistent factor in
ongoing depression symptoms in adolescents and are generally related to the influences on
behaviors that peers exert, especially with alcohol and substance use in both genders (Huang et
al., 2014; Herres, & Kobak, 2014; Pesola et al., 2015). As noted above, alcohol and substance
use is linked with an increased risk for depression in adolescents.
The actual school environment (or lack thereof) seems to have a strong influence on the
potential risk for depression as the stress of academic and social pressure is increased.
Haarasilta, Marttunen, Kaprio, and Aro (2004) found that adolescents, especially between the
ages of 15-17, were more apt to experience a major depressive episode if they smoked cigarettes,
had chronic medical conditions, and/or did not work or attend school at the time of the study.
The school environment and poor school functioning has been associated with depression in the
influential factors of academic performance, the perception of prejudice/discrimination by peers
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and/or teachers, and socioeconomic status (Respress et al., 2013; Seeley, Stice, & Rohde, 2009).
Interestingly, the perception of peer prejudice and teacher discrimination was significantly
related to depressive symptoms with the teacher as a much stronger influence than the peers
(although this finding was mostly in whites and minorities and not with blacks); parental
education and neighborhood poverty had a more powerful influence with black adolescents.
School performance has also been linked to depressive symptoms; Respress et al. (2013)
found that low GPA (grade point average) scores were strongly associated with depressive
symptoms for all racial groups. Perception of discrimination in the school setting was an
additional predictor for depression in this study. Wanner, Morin, and Vitaro (2005) found that
the risk for a depression trajectory was much higher for girls with a greater level of a reactionary
temperament who were rejected by their same sex peers. This contrasts the earlier theme of
negative peer influence even though the outcome is similar; rejection is more of a behavior
dictated by others while a negative peer influence involves behaviors that are controlled by the
individual based upon the peer influence (although this vulnerability may stem from peer
rejection initially). The school environment can have a robust impact on a youth’s health both
positively and negatively. Negatively, this may occur when a teen feels discriminated against by
classmates and teachers; teachers are supposed to be accepting of all kids and have a huge
influence on academic performance. Thus, a perceived relational instability can lead to
associating with peers who may also feel shunned and who display acting out/risky behaviors,
potentially leading the teen to start smoking and drinking. If the teen has the ability to make
friends who are not of the risk-taking circles those friends may be able to help offset the
influence of the shunned group.
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Family factors
The effects of a dysfunctional school environment and/or peer influences are not the only
possible predictors for the onset or course history of depressive symptomology in adolescents.
It is well known that adolescents who experience parental conflict are at a greater risk for
depression (Connell & Dishion, 2008). Parental influence on adolescent depression is not
relegated solely to conflict, however. Ideally, the family serves as a source of stability during a
tumultuous time in the life of a young person, and if a teen does not perceive that the family as
whole functions on a stable and secure level then the teen has a difficult time obtaining the
emotional permanence needed for self-efficacy. Lack of parental support and stability can shake
the foundation of an adolescent’s identity of self with a negative impact on overall social
functioning through the lifespan. This insecurity and instability appear to have a profound
influence on a youth's emotional well-being. Dumont and Olson (2012) studied somatic and
emotional predictors for depression in primary care and found significant associations with
stress, anger, and worries about family substance use on positive depression screens. An
adolescent’s perception of family security regarding the future and the ability to give support
could influence the increase or decrease in depressive symptoms, especially in the area of
financial concerns; this factor especially affects adolescent females (Forman, & Davies, 2003;
IOM, 2011; Seeley, Stice, & Rohde, 2009).
Gender
The mechanism by which risk behaviors affect girls seems to be different than in boys,
resulting in a wide variety of outcomes between the two genders. This divide includes the
majority of risky behaviors in which this population engages: BMI and body image, substance
use, sexual activity, relationships, and smoking. When boys and girls were compared with the
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same risk behaviors of moderate substance use and sexual activity, girls consistently had more
depressive symptoms than boys; the recommendation was made that girls who engage in highrisk behaviors, even at the experimental level, should be screened for depression (Waller, et al.,
2006). This seems to be specifically the case for sexual activity. The association between sexual
activity, sexual risk behavior, and depression symptomology in females is especially strong. Of
the reviewed studies that addressed sexual activity and sexual risk behavior in adolescence, all
noted that higher levels of depressive symptoms were found in females that engaged in greater
sexual risk behavior activity, but it was unknown if prior histories of depression could have
potentially contributed to this behavior or not (Rubin, Gold, & Primack, 2009; Seeley, Stice, &
Rohde, 2009; Khan et al., 2009; ACPM, 2011; Waller et al., 2006). For example, Waller et al.
(2006) found that every risk behavior among females increased the risk for depression symptoms
in adolescence.
The need for emotional permanence and security seems especially relevant since young
women appear to be more strongly influenced by rejection and perceived instability in their
relationships (Grant et al., 2006; Seeley, Stice, & Rohde, 2009). This perception would logically
increase the risk for an adolescent trajectory for depression into adulthood (Yaroslavsky et al.,
2013). Although negative perceptions in the area of interpersonal relationships affected both
genders, they found that girls were affected differently, which supports the ACPM's (2011)
recommended guideline for adolescent depression. Having a tendency to ruminate on negative
inferences from a traumatic event, or just making negative inferences in general, was positively
related to depressive symptoms in adolescent girls, especially in the areas of achievement and
appearance (Rood et al., 2012; ACPM, 2011).
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Internal Factors
Depression in youth has unique characteristics: specific negative thoughts that are
generally self-defeating, and a lack of positive thoughts. The social information-processing
(SIP) model helps providers to understand how depression and anxiety relate to negative
cognitions, particularly those cognitions that relate to negative outcome expectations or negative
appraisals of behaviors and situations. The SIP model also helps illustrate the tendency of
depressed youth to “sitting in the problem” instead of finding solutions to solve it (Luebbe, Bell,
Allwood, Swenson, & Early, 2010). This “sitting in the problem” is not necessarily rumination
but more of an inertia that can be related to the fear of failing, comfort with being in a victim
mentality, distrust of self and others, or an overall fear of a negative outcome. This negative
perception of self and the world can lead to feelings of isolation, either self-imposed or
otherwise, which can lead to deviant peer influences (discussed in the first theme).
Understanding this model in relation to adolescents is important to identify the potential “red
flags” when assessing for the presence of any psychiatric condition.
A sense of powerlessness, feeling like a failure, insecurity, and feelings of helplessness
nurture a negative outlook and perception of a teen’s life, leading to a pessimistic sense of self
both internally and externally. Taking credit for a personal success becomes very difficult as it is
attributed to “blind luck.” Self-reported low levels of coping, feelings of loneliness, and
interpersonal dependency have been reported at higher percentages for those individuals who
screen positive for depression (Yaroslavsky et al., 2013), as well as increased irritability and
anger (Hagan, Shaw, & Duncan, 2008; Dumont, & Olson, 2012). Luebbe, Bell, Allwood,
Swenson, and Early (2010) noted that not only were anxiety and depression related to a more
negative information processing style, but depression alone was related to a lower positive style
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as well (a positive style is the ability to perceive the environment and self in a more optimistic
view). As noted previously, negative cognitions are positively related to depressive symptoms,
and this phenomenon is notably reported more frequently in females. Negative processing of
social information and perspective is also apparent with other externalizing symptoms such as
obesity, sedentary behavior, and unhealthy sleep hygiene (Rockhill et al., 2013; Carli et al.,
2014; ACPM, 2011).
Discussion
Based upon this review of the literature the mental health domains on risk screening
instruments, which includes depression, anxiety, self-harm, and suicidal ideation/behaviors, does
not stand alone in alerting the clinician to the need for further depression screening in
adolescents. Tobacco use, alcohol/drug use, violence, adolescent stress, obesity, sexual
promiscuity, and the lack of protective factors (such as peer influence, school connectedness,
supportive adult relationship) are additional domains that need to be considered when evaluating
for the presence of depressive symptoms in this population. Although each article in this
literature review was not of high quality, they clearly linked adolescent characteristics and/or
behaviors with depressive symptoms. While the same behaviors and/or characteristics were not
studied across all of the articles, they did collectively focus on the traits that are very prominent
in the teenage years.
Due to the high numbers of adolescents who suffer from depressive symptoms—without
the benefit of any treatment—taking a few moments to thoroughly evaluate the domains on risk
screens in a larger context may benefit many adolescents by alerting the clinician to the need for
further assessment and/or treatment; this is the ultimate goal. Most importantly, the results of
risk screening behaviors must be interpreted with a more discerning eye than is currently seen in
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practice. This is essential when teens engage in high-risk sexual activity, particularly in females,
who report problematic or dysfunctional family/social relationships, and/or are unable to identify
positive qualities about self. Family discord, problems with a boyfriend or girlfriend, or schoolrelated problems have been reported as a few of the more common reasons for adolescent suicide
in the age group of 13 to 17 (Kennebeck, & Bonin, 2015). Also, because depression is not
identical in presentation as adults, providers need to pay close attention to the uncommon
symptoms of depression in youth: school problems, boredom, emotional sensitivity, frequent
unexplained physical illness complaints, inability to concentrate, irritability, self-harming
behaviors, and sleep disturbances (ACPM, 2011; Maurer, 2012).
The purpose of this literature review was to examine some of the variables associated
with the development of depression in adolescents or its clinical course in relation to CDC
(2013) recommended risk behavior domains on risk screening tools. Ideally, studies included in
this paper would all be based upon the use of consistent risk behavior screening instruments
however; studies on factors contributing to depression in adolescents were also included. Two
other risk behavior-screening instruments besides the RAAPS were recommended by MQIC
(2013): the Adolescent Health Review (AHR,) and Bright Futures (Patient Health Questionnaire
for Adolescents [PHQ-A], 1999) but research studies with those tools in relation to depression
identification were not found. In the absence of more studies from which to infer, the studies
evaluated in this literature review primarily point out the areas that can be potential indicators in
risk behavior screening. The rationale for this review was the premise that depressive symptoms
in youth may be linked to several risk factors that are not seen in adults such as family, gender,
school environment, and internal factors, and identification of these factors could aid clinicians
in conducting a more comprehensive assessment. Future research should examine and evaluate
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other risk behavior screening tools for similar outcomes with the tools recommended by
USPSTF.
Unfortunately, the lack of consistency in screening instruments and methods used in the
studies for this literature review create a limitation as well as the inability to show causality
between the variables and outcomes. The designs of the majority of the studies were not of high
quality, although several showed good reliability and validity. Lack of randomization,
inconsistent demographics, samples, and settings hindered the generalizability of the results.
Only one study had any longitudinal data recorded, and that was of a 24 month time period.
Further research should be focused on the use of consistent screening instruments within similar
settings, samples, and long-term follow-up. Several areas of research could include an emphasis
on gender as a mediating variable since gender was a significant factor in the outcome of several
studies. Other recommendations for future research should examine the differences and
frequencies in positive results on the domains of risk behavior screening with the influence of
race, socioeconomic status, gender, and legal guardianship of the adolescent; is there correlation
between these factors and a positive screen for depressive symptoms? Lastly, primary care
providers need to consistently and diligently follow guidelines with regard to screening practices
for their particular setting. If only a portion of providers actually screen as suggested, the gap for
identifying these vulnerable adolescents will remain no matter what screening instrument is used.
Conclusion
In lieu of adolescent depression specific screening, risk behavior screening may be a
more viable option in the primary care setting; it can alert the provider to an overall elevated risk
assessment that leads to further screening. When the depression specific domains on risk screens
do not elicit a positive result the provider should take into consideration other domains showing
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positive results to evaluate for the potential presence of adolescent depression. The CDC (2013)
recommends using risk behavior screening tools with the inclusion of domains that are the
leading causes of adolescent morbidity and mortality: unintentional injuries/violence; mental
health; tobacco use; alcohol and other drugs; sexual behaviors contributing to unintended
pregnancy, STIs and HIV; dietary behaviors; physical activity; and protective factors (MQIC &
AHRQ, 2013). The recommended risk screening instruments contain these domains and are a
reliable and valid measure for adolescent risk assessments. Guidelines regarding the
interpretation of the screening results, as it relates to potential adolescent depression, should be
developed so that adolescents needing further evaluation do not fall through the cracks in terms
of receiving adequate treatment for depression.
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Introduction
Researchers estimate that the prevalence of youth depression in the primary care setting
is as high as 28% (American College of Preventive Medicine [ACPM], 2011). Statistics in a
2009 report from the National Research Council (NRC) and the Institute of Medicine (IOM)
noted that the point prevalence of mental, emotional, and/or behavioral disorders among youth
ages 12 to 17 is estimated at 14-20%, and symptoms may start to appear two to four years prior
to the disorder being fully recognized. The NRC also reported that mental health problems
started by age 14 in half of all cases, with the lifetime prevalence upwards of 20%. The National
Strategy for Suicide Prevention (2012) stated that for students in grades 9 to 12, almost 16%
seriously considered suicide and 7.8% of students had attempted suicide at least once in the prior
12 months; 60% of adolescent depression sufferers reported having suicidal thoughts with 30%
actually attempting suicide.
Mental illness in youth has significant consequences for the health care system,
particularly related to financing care. For example, the average cost of an adolescent inpatient
care stay with a primary diagnosis of an affective disorder, particularly, was $13,397 per stay;
total charges for 67,404 reported stays (admissions) equated to $903 million dollars for 2006 (the
most recent data reported) (O’Connell, Boat, Warner, 2009). In addition, adolescents with
depression experience multiple negative outcomes that can be life-long. The most significant
cost of adolescent depression to society is the personal suffering from mental health problems
due to increased morbidity that extends from psychological suffering (substance abuse, physical
health consequences, lost occupational productivity) and decreased health-related quality of life.
In the United States, depression and alcohol abuse are reported to be part of the top five causes
of premature death and disability (Michaud et al., 2006). In addition, adolescent depression has
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a negative effect on the health and well-being of family members and significant others such as
parental/caregiver loss of employment because of the unpredictability and stress from having a
child suffering from mental illness, or the decreased attention and focus to the needs of other
family members due to so much energy consumed by a sick child (Busch & Barry, 2007).
Benefits to earlier diagnosis and treatment include reduced future medical costs; reduced
expenditures for social and educational programs subsequent to reduced drug abuse, costs
associated with involvement in the judicial and legal systems, and losses from student dropout
rates.
Risk behavior screening can increase the likelihood of identifying youth with depression
in a primary care setting. The need for reliable evidence on outcomes resulting from risk
assessments, and consequent early detection and treatment of depression is imperative to
improve quality of life and reduce treatment costs. The purpose of this paper is to describe
findings from a study that investigated patterns of risk behavior screening in an adolescent health
clinic and discuss implications of the findings for Psychiatric-Mental Health Advanced Practice
Registered Nurses (PMH-APRN) with Doctor of Nursing Practice (DNP) degrees.
Background
Since 2009, the US Preventive Services Task Force (USPSTF) has recommended
screening for adolescent depression in primary care. However, the proportion of depression
screening has been below recommended rates, perhaps due to time constraints in the primary
care setting. (USPSTF, 2009; Irwin, Adams, Park, & Newacheck, 2009).
In addition to the issue of time constraints, depression screening has been suboptimal for
identification of depression in adolescents in primary care due to the use of depression screening
tools that assess symptoms commonly seen in depressed adults, rather than behaviors linked to
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depression specifically in the adolescent population. Assessing for the presence of behaviors that
are considered dangerous for an adolescent’s health and well-being is not only informative
regarding overall health status but may reveal the potential need for further mental health
assessment and/or treatment. The Centers for Disease Control and Prevention (CDC, 2010) has
identified the leading risk behaviors for morbidity and mortality in adolescents and
recommended evidence-based risk assessments for these behaviors, or domains, in the primary
care setting. These include unintentional injuries/violence, mental health, tobacco use, alcohol
and other drugs, sexual behaviors contributing to unintended pregnancy, STIs and HIV; dietary
behaviors, physical activity. In addition, a number of protective factors have also been identified
as important to assess, including strong social support systems, acknowledging good qualities
about self and having future goals, and/or a positive and trusting relationship with an adult
(Michigan Quality Improvement Consortium [MQIC], 2013).
Adolescents who engage in risky behaviors are vulnerable to problems with current and
future mental health issues such as major depression, substance use, or other psychiatric
disorders, unintended pregnancy, poor school performance, and/or diminished social functioning.
In addition, adolescents who experience depression have higher rates of engaging in these risk
behaviors compared to adolescents without depression, thus increasing the risk for further mental
illness into adulthood (Institute of Medicine [IOM] and National Research Council Committee
on the Science of Adolescence, 2011; Waller et al., 2006). Since 2013, the MQIC and the
Agency for Healthcare Research and Quality (AHRQ) have recommended that risk behavior
screening be conducted at least annually with a validated screening instrument. Currently, a lack
of systematic evidence-based guidelines for the use of risk assessment screening instruments for
providers in the identification of potential depression in adolescents exists. However, evidence-
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based studies have identified risk behaviors described by the CDC that are associated with the
increased risk for depression (IOM, 2011; Forman & Davies, 2003; Haarasilta, Marttunen,
Kaprio, & Aro, 2004; Richmond, Mermelstein, & Metzer, 2012).
Study Overview
The purpose of this retrospective chart review was to investigate provider patterns of risk
behavior screening among adolescents who receive treatment at an adolescent health clinic in an
urban setting in a south-central state of the US. The following research questions were explored:
1. Do providers adhere to national guideline recommendations for risk behavior screening of
adolescents in a primary care setting?
2. What are the patterns of provider screening for depression screening using the PARS among
adolescents in the clinic?
3. What are the patterns of behaviors and risk level among adolescent patients treated at the
clinic?
The study procedures were approved by the Medical Institutional Review Board at the
sponsoring university. Procedures to protect subject confidentiality were followed throughout
the duration of the study. No data/names of physicians or providers were examined, extracted, or
recorded. All data were de-identified prior to being recorded on the data extraction form and
were not able to be traced back to the original medical record. All protected health information
reviewed was not printed or recorded.
Methods
Sample. The sampling frame consisted of 605 medical records of patients seen at the
clinic between March 1, 2014 and March 31, 2014. Records from this sampling frame were
randomly selected (using Randomizer.org) and reviewed for eligibility in the study. A total of
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150 records were reviewed to obtain the final sample size of 84; sample size was based upon the
number of variables examined with an over-allowance of four medical records included in the
event of conflict or exclusion during review.
Inclusion and exclusion criteria. Inclusion criteria included all adolescents, regardless
of race, ethnicity, or gender between 12 and 18 years of age at the time of the clinic visit;
patients seen for any reason during normal operational hours between March 1, 2014 and March
31, 2014 were eligible for inclusion. Exclusion criteria included adolescents with severe
intellectual disability as documented in the medical record, non-English speaking adolescents,
patients seen primarily in the rheumatology clinic, and patients seen as add-ons for sick visits or
blood draws.
Setting. The study was conducted in a primary adolescent health services clinic located
in an urban area of a south-central state of the US. Clinic staff includes social workers,
nutritionists, psychologists, physicians, and nurses who provided a broad range of services.
Services include specialty programs in obesity medicine and a Young Parents Program. The
clinic also provided treatment for chronic illness, reproductive care, nutrition counseling,
physical exams for school, sexual abuse evaluation and treatment, substance abuse services, and
behavioral problems counseling. The operating hours of the clinic were from 9AM to 8PM
Monday through Thursday and 9AM to 4PM on Friday. An average of 750 patients were seen
every month. The records for the sample in this study were comprised of paper medical records.
The clinic utilizes the Perkins Adolescent Risk Screen (PARS) for risk behavior assessments
(Appendix A); a 17-item questionnaire, administered by the provider, that assesses for risk and
protective factors and includes all CDC recommended risk areas. Patients are to be screened no
less than annually at visits to the clinic per the MQIC (2013) recommendation.
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Data collection. Medical records were reviewed for 1) date of service, 2) age, 3) gender,
4) race/ethnicity, 5) last education grade completed at time of visit, 6) who patient legally resides
with 7) reason for visit, 8) documented PARS in chart, 9) risk level assessed for each domain on
PARS, 10) documentation of provider referral and reasons, and 11) prior documented history of
depression and/or anxiety. All data were extracted from each medical record by the principle
investigator using a demographic collection form (see Appendix B) and study variables data
extraction form (Appendix C).
Analysis. Rate of overall provider screening for risk behaviors using the PARS
screening instrument was calculated based upon the presence of the most recent PARS in the
chart. Descriptive frequencies were initially calculated to assess for differences in the screening
practices of providers based upon completeness of the PARS. Fisher’s exact test was performed
to measure the differences in provider screening assessment patterns by gender and race
(screened and/or not screened). Five risk behavior domains on the PARS were chosen to
investigate: Sexual Activity, Drug Use, Family Relationships and Responsibility, Friends and
Recreation, and School. Significance in risk behavior and risk level was computed for gender
using Mann-Whitney U; for race and with whom the patient lives using Kruskal-Wallis Test.
Data were analyzed using the SPSS software, version 22.
Findings
Patient Population
The mean age of the 84 adolescents was 15 (SD = 1.7). Patient visits were made up of 61
females (72.6%) and 23 males. Caucasians made up 52.4% of patients, 33.3% were African
American, 7.1% were of mixed race, and other/unknown was 7.2%. Generally the last grade
completed was 12th grade (25%), which coincides with the age of the patients. The adolescents
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generally lived in either a one-parent household (41.7%) or two-parent household (31%). Out of
the 84 clinic visit dates reviewed, 21 visits (25%) were due to a psychiatric-related complaint. A
history of mental health treatment prior to the reviewed PARS screening was present in 33.3% of
adolescents; females accounted for 26.2% of prior psychiatric treatment and males 7.1%.
Seventeen adolescents (20%) were referred for further assessment and/or treatment on the date of
the PARS screening (percentage based upon 84 charts); 15 females and two males, the majority
were referred to the dietician for high BMI or to mental health providers for depression and/or
anxiety symptoms or for behavior problems. The age range of those patients screened was 12
years for the youngest and 18 years at the oldest. The mean age for the most recent screening
was 15 years and the mean age at data collection was 17 years (demographics, Table D1).
Screening
Out of the 84 charts reviewed for this study, 7 of the charts (8.3%) did not have a
screening instrument in the chart, did not have documentation that a screening had been
performed, or had a completely blank screening PARS sheet in the chart. The provider rate for
annual screening for risk behaviors (according to the recommended guidelines) in this clinic was
approximately 33.3% of the time; screening was performed within 1-2 years of the prior
screening 44% of the time; and the rate for screening that was over 2 years from the prior
screening was 22.7% of the time. Results showed that nearly a quarter of the patients reviewed
were not being screened within a 2-year time period, and the longest time interval between a
PARS screening was 6 years; several charts were found to have 4 and 5 years between
screenings. Less the seven charts without any screen, only the domain of “Tobacco use” had a
100% completion rate; the domain “Good qualities and future plans” was the least completed
(left blank) at 30% (Table D2, completion percent). There was not normal distribution for any of
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the statistical results. Following chi-square analysis there was no significant association between
the variable race and the presence of a PARS screening in the chart and at least partially filled
out (n=80; p= .67) and/or if a referral was made (n=79; p= .30), and with whom the patient lives
with, the presence of a PARS in the chart (n=82; p= .28), and/or if a referral was made (n=81; p=
.934); Fisher’s exact test did not find significant association between gender and presence of a
PARS in the chart (n=84; p= .67) or if referral was made (n=83; p= .13) (Table D3). Complete
counts for all risk behavior domains on the PARS stratified by gender are present in Table D4.
Characteristic of Patient Outcomes
Mann-Whitney U tests revealed no significant differences (p < .05) in the risk level with
School Issues of males (n=20) and females (n=52), U=463.5, z= -.958, p= .34; Friends/Fun of
males (n=20) and females (n=50), U=474, z= -.557, p= .577; Family of males (n=21) and
females (51), U=493.5, z= -.832, p= .41; Drug use of males (n=22) and females (n=54),
U=583.5, z= -.190, p= .849; and Sexual Activity of males (n=21) and females (n=49), U=439, z=
-1.241, p= .215 (median scores across genders and variables = 1.00). Kruskal-Wallis Test
revealed a statistically significant difference between the variable Sexual Activity across the
three races (Caucasian, n=37; African American, n=24; Other, n=6), chi-square (2, n=67) = 6.37,
p = 0.41; mean rank showed that African Americans had the highest Sexual Activity risk level
scores compared with Caucasians and Other races (medium scores across all races and variables
= 1.00) (Table 1).
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Table 1
Mean Rank Between Domains and Variables of Gender and Race

School Issues

Friends/Fun

Family

Drug Use

Sexual Activity

School Issues

Sexual Activity

Drug Use

Family

Friends/Fun

Sex

N

Mean Rank

Male
Female
Total
Male
Female
Total
Male
Female
Total
Male
Female
Total
Male
Female
Total

20
52
72
20
50
70
21
51
72
22
54
76
21
49
70

39.33
35.41

Race

N

Mean Rank

Caucasian
AA
Other
Total
Caucasian
AA
Other
Total
Caucasian
AA
Other
Total
Caucasian
AA
Other
Total
Caucasian
AA
Other
Total

38
24
7
69
37
24
6
67
40
26
7
73
37
25
7
69
36
24
7
67

33.53
37.00
36.14
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Significance (p < .05)

.338
34.20
36.02
.577
34.50
37.32
.405
38.02
38.69
.849
31.90
37.04
.215

Significance (p < .05)

.651
30.59
40.13
30.50
.041
37.45
37.65
32.00
.546
34.93
35.20
34.64
.993
36.47
30.38
33.71
.158

When comparison of mean scores of the five risk behaviors using a Mann-Whitney U
Test was made between males and females, although no significant results were found, females
were found to have higher risk scores compared with males for all the risk variables except
within the variable “School issues,” in which males were higher. African American females
reported the highest proportion of risky sexual behavior levels compared with males and other
ethnicities.
Discussion
The primary finding of this review was that provider screening practices varied without
any pattern of bias; overall completion rate was poor (Table D2). The presence of a fully
documented PARS in the chart was not shown to be related to, influenced or affected by gender,
race, age, or any other demographic data that were collected. The majority of the risk behavior
screenings (>60%) did not take place annually, as was the recommended time frame; for several
adolescents screening had not taken place in over 3 years. Only one risk behavior domain
(“Tobacco use”) was filled out with 100% completion (minus the seven charts that did not have
any part filled out or was not in the chart). Overall, many of the risk behavior domains on the 77
PARS that were in the charts were left blank. Due to so many incomplete risk behaviors
domains, it is difficult to accurately identify relationships between variables. It would be
interesting to understand why providers filled out only certain risk factor domains over other
domains.
In addition to wide variation in screening patterns, it was noted that African American
(AA) females have higher rates of elevated risk levels in the area of sexual activity. Studies have
reported that when boys and girls were compared with the same risk behaviors of moderate
substance use and sexual activity, girls consistently had more depressive symptoms than boys;
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the recommendation was made that girls who act out in risk behaviors, even at the experimental
level, should be screened for depression (Waller et al., 2006). This seems to be specifically the
case for sexual activity. The association between sexual activity and sexual risk behavior and
depression symptomology in females is especially strong. Of the reviewed studies that addressed
sexual activity and sexual risk behavior in adolescence, all of them noted that higher levels of
depressive symptoms were found in females that engaged in greater levels of risky sexual
behavior; it was unknown if prior histories of depression existed that may have contributed to
this behavior (Rubin, Gold, & Primack, 2009; Seeley, Stice, & Rohde, 2009; Khan et al., 2009;
ACPM, 2011; Waller et al., 2006). Being female and African American was associated with
elevated sexual risk behaviors and is an area of needed research for the PMH-APRN to explore
in his/her practice and use the findings as an opportunity to better serve this population.
One-third of the patients in this study had a prior history of mental health problems, a
particular variable that was not specifically studied with this review. The PMH-APRN can and
should be especially vigilant for depressive symptoms in these patients, as a previous history of
mood disorder have been shown to increase the risk for developing depression later in life
(American Foundation for Suicide Prevention, 2013).
Preventative visits provide the perfect opportunity for APRNs to assess the patient’s
overall sense of well-being, including the psychosocial well-being. Advance Practice Nurses
(from all specialty areas) are the principle health care contacts for a large majority of patients
with mental illness (Young, Miller, & Khan, 2010), and they need to be skillful at identifying
depression in adolescents as well as open to “different” symptoms of depression. This means
utilizing a team-based approach with the PMH-APRN collaborating with other healthcare
professionals who are involved in the patient’s care, as well as directing members of the team to
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the most up-to-date evidence-based information pertaining to identification of mental illness in
this patient population.
Limitations
The major limitation for this review is the lack of ability to generalize study results to the
general population of patients who were not seen at a health clinic. The sample size was small
considering the number of charts reviewed and that the sample was taken from a health clinic in
a large teaching hospital. Because this hospital is a primary resource for Medicaid patients,
many of the charts included Medicaid. To have a broader population included in a review,
information would need to be gathered in different areas of the country where the sample
population may have more varied demographic characteristics. In addition, the rate of
completion for provider adolescent screening utilizing the PARS was very low and the provider,
not the patient, administered the screening tool. This could mean that results were biased.
Different providers prioritize risk behaviors at varying levels of importance in relation to the
adolescent’s health and may not be based upon the priorities the adolescent feels are important
for health and well-being. Furthermore, providers were not interviewed to elicit information
regarding screening practices and general thoughts on screening using the PARS for the presence
of high-risk behaviors, especially those behaviors potentially masking depressive symptomology
and the barriers to screening.
Implications for Practice
The American Association of Colleges of Nursing [AACN] (2004) has explicated several
core competencies for Advanced Practice Nurses who hold Doctor of Nursing Practice (DNP)
Degrees. These DNP competencies, or essentials, include a focus on advanced practice nursing,
population health, clinical scholarship, interprofessional collaboration, policy, and organizational
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and systems leadership. These competencies provide direction for PMH-NPs with DNP degrees
to improve clinical practice and optimize outcomes for adolescents at risk for depression. First
and foremost, screening is an integral aspect of the assessment of the adolescent in primary care,
for the purpose of identifying and treating a major depressive disorder. Improving the services
provided to patients is the main goal of this Capstone. For the potential barrier of time,
strategies, which focus on increasing the time-effectiveness of screening, might include
incorporating a brief screening instrument to be completed by the adolescent in the waiting area
such as the PHQ-2. The PARS is a 17-item questionnaire to be filled out during the health visit,
but it can be time-consuming due to the length and amount of information it asks to obtain. To
this regard, the doctoral-prepared PMH-NP could contemplate making short-term follow-up
appointments for adolescents who present with psychiatric complaints and/or a positive risk
behavior screen on one or more domains, especially the domains that relate to adolescent
depression and anxiety.
Findings are also relevant for population health. For example, strategies to promote
awareness of depressive symptoms in this population and decrease the stigma are warranted; the
general public needs to be aware that the depressive symptoms in a young person rarely appear
the same as in an adult. The DNP prepared PMH-APRN is well-suited to go into schools, both
public and private, to promote information regarding depression symptoms and screening and
distribute educational materials in areas students may or hold workshops.
Clinical scholarship can be advanced with further research related to elevated risk
behaviors and the relationships they have on depressive symptomology and diagnosis among
adolescent depression. Additional domain areas need to be included or could replace other
domains when assessing for depression and other mental health issues in order to stay current.
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These new domains may include hours spent watching TV, playing video games, or texting;
measuring BMI/nutrition with kind of food being consumed. Other important health behavior
measures include how many hours are spent alone and family history of mental health issues.
The demographic variables of race and gender should be considered as well and possibly
separated using different screening methods; males and females screened with different
screening instruments. Other areas to consider for future research would be to explore the
relationships between adolescents who are referred due to an elevated high-risk behavior profile,
reason for referral, and the effect of successful/unsuccessful treatment interventions.
PMH-NPs with DNP degrees can engage in clinical scholarship in collaborative efforts
with other disciplines. Outcomes research conducted in collaboration with primary care allows
the PMH-APRN with a DNP degree can assess these screening practices and help them to evolve
and become more accurate, less time consuming, and improve overall clinical practice services
to this patient population.
This retrospective review mimics findings of other studies in manuscript 2, in that
adolescent depression and risk behavior screening are at suboptimal levels in primary care.
Patient-centered care is the current model for patient care and incorporating behavioral health is
a natural integrative component and a priority to address service quality, service cost, and service
availability. The PMH-APRNs with a DNP degree are poised to lead this integrative
progression. The adolescent health clinic for this project has a fairly reliable and reciprocal
relationship with their behavioral health colleagues (per medical record reviews for this study).
The concern surrounds the screening process, which includes: the provider actually using the
screening tools per the specific clinic and completing it, minimizing provider bias and
interpretation on the screening domains, and identifying other areas of the assessment screening
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that may be relevant to adolescent depression. In the primary care clinic, the DNP prepared
PMH-APRN is ready to assist in creating policy and procedures for this clinic regarding
adolescent depression screening. Part of this process would include properly training the
primary care providers in mental health skills as well as ongoing consultation to help them
diagnose and/or manage adolescents with basic mental and behavioral health issues. T
The PMH-APRN with a DNP can construct this training program that would consist of
skills to better communicate with parents and/or teachers, use of screening measures, listening
for the hidden “red flags” in the information given by the adolescents, and focusing on somatic
complaints by the patient. The program would also require annual retraining to ensure that the
most up-to-date evidence-based interventions were being disseminated throughout the clinic.
Outcome measures would be collected in provider fidelity with screening, provider comfort with
mental health care in adolescent patients, follow-up tracking of depressive symptoms in the
adolescent, family feedback, and the effect on numbers of adolescents identified with depression
and successfully treated by the primary care provider. The program created and implemented by
the PMH-APRN with a DNP can be a blueprint for other clinic areas, including primary pediatric
health and other settings of the clinic such as satellite offices.
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Conclusion
As described in the first manuscript, adolescents are being prescribed antipsychotic
medications at an alarming rate for a multitude of reasons—behavior problems being one of the
top reasons, even among children 2-5 years of age. It can be reasonably assumed that these
medications may have far reaching consequences on the physical and mental health of a young
person. Many behavior problems that youth are being treated for with antipsychotic medications
are also used to treat other mental health problems such as depression and anxiety.
Unfortunately, many clinicians may be unaware that some of these behavior problems could
have other causes and may actually stem from depression. While limited research exists
evaluating the risk behavior variables identified by the CDC (2012) and their influence on the
presence or absence of depression, enough research has been completed to support a more
exhaustive inquiry into certain risky behaviors, such as smoking or drug use, when assessing an
adolescent. The holistic approach to patient care that is inherent in nursing is a core component
of Advanced Practice Nursing; this holistic base is the foundation of the exhaustive inquiry that
is needed to accomplish a more thorough assessment of these patients. Since 2009, the US
Preventive Services Task Force (USPSTF) has recommended screening adolescents (age 12 to
18 years) for depression when systems for diagnosis, treatment, and follow-up are in place.
The second manuscript explored adolescent risk behaviors in relation to the presence
and/or development of adolescent depression. This focused primarily on those behaviors not
normally associated with the existence of depression, at least not in an adult. Many symptoms
are constant between adults and youth, but many are not. Youth “act-out” in risky behaviors
much of the time when psychopathology is present. For example, common behaviors include
risky sexual behaviors, anger and aggression, and increased conflict with family. This is
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partially due to the adolescent continued brain development, hormonal fluctuations, and the
sense of social and personal identity that is ill defined at this particular time in a person’s life.
This makes it all the more a priority to correctly identify mental health areas that need to be
addressed and treated, if indicated. All of the developmental components of this population
create an uncertain and unpredictable future, and the path of this future is fluid, at least to a
certain extent. It is imperative not to provide suboptimal care; this would be a disservice to their
future.
The final manuscript described results of a descriptive study examining risk behavior
screening practices using the PARS risk behavior assessment at an adolescent primary care
health clinic in the southeastern United States. Several questionable practices related to provider
fidelity in screening were identified. The most pressing concern involved the lack of consistent
screening overall, across all genders, races, ages, and patient presentation. Lack of completeness
of the screening instrument was consistent. Strategies that focus on increasing clinician fidelity
and consistency regarding depression screening among adolescents have been proposed.
Recommendations for improving screening rates in institutions included incorporating a
brief screening instrument in the waiting area for the patient to fill out prior to being called back
for examination; increasing public and private school awareness with literature and expert
speakers; follow-up appointments for a patient with any elevated risk behavior scores, even if not
in the domain of depression; the addition of other domains on risk screening instruments; and
various research areas to further identify relationships between risk behaviors and depression.
Significant challenges exist in terms of creating and defining regulations, guidelines, best
practice recommendations, and policy regarding depression screening in the adolescent
population. In the first manuscript one of the challenges found was related to the use of

66

alternative treatments over medication (alternative in this context to mean some form of
psychotherapy or non-medication treatment). Some of these challenges are associated with
provider reimbursement, lack of dissemination of research outcomes into practice, and obstacles
introduced from families. Part of the training and expertise rooted in a DNP program is the
ability to shape policy and practice on many levels. For the particular example of using
alternative treatments prior to medication in young people, a DNP prepared nurse can help to
generate changes within communities in regards to this issue, such as taking the lead in creating
local programs with a primary purpose to offer psychotherapy to young people at a maximally
reduced cost and that is easily accessible. Monitoring outcome data from this venture as
supportive indicators can help a DNP nurse continue to advocate for changes within the
insurance systems, within federally funded programs, and ultimately to policymakers in order to
decrease the challenges associated with other treatments over medications as a first-line option.
If access to care is a problem due to lack of providers, the DNP clinician can also work
toward finding avenues that will increase provider availability. Again, this can be done through
policy change or through grass roots efforts in a particular region. Incorporating the input and
support from other disciplines affected by having insufficient numbers of clinicians to provide
treatment/care for patients can also contribute strength for change in conjunction with the DNP.
Much of the responsibility of care in areas underserved by mental health falls on the primary care
provider. Therefore, these providers, along with social workers, clinical psychologists, state
child welfare offices, and others can contribute vital clinical insights when seeking solutions to
this issue. Healthcare is shifting to more of a community-based approach, which means that the
healthcare “team” approach will be the standard model. The DNP PMH-APRN has the

67

preparation to lead these teams into the most optimal, patient-centered care design that will
successfully help the patient achieve their highest level of health.
All of the suggestions for future research in these manuscripts are areas in which the
DNP PMH-APRN has a large investment at stake. Many DNP PMH-APRNs are at the forefront
of patient care, ensuring the most recent evidence-based information is being accurately reflected
in practice. But they also advance the evidence-base related to best practices. Best practice
guidelines and recommendation are non-existent without the monitoring and dissemination of
accurate information generated from well-designed research. In practice, the DNP provider
collects and records the pertinent data from patient interactions, analyzing it for areas of potential
improvement or change, researching for existing information that has addressed this particular
area, recognizes if a need exists for further investigation, and seeks alternatives to solve the
clinical problem.
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Appendix B
Demographic Collection Form
Date of Review:

Date of Service:

Medical Record Screening ID #:

Medical Record Assigned ID #:

Age:
Male
Female
Race/Ethnicity:

County of Residence:

Last Education Grade Completed:

Lives Primarily With (1-parent, 2-parent,
3-gparent, 4-other family member, 5-other)

Reason for Visit:

Diagnosis:
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Appendix C
Data Extraction Form
Domains on PARS

PARS included in
chart

Risk level
assessed

BMI
Weight perception
Nutrition
Exercise
Tobacco use
Drug use
Alcohol use
Sexual activity
School
Depression
Abuse
Safety
Violence
Family relationships and
Responsibility
Friends and Recreation
Good qualities and Future
plans
Immunizations
PARS in chart: 1 = yes; 2 = no
Risk Level: 0 = N/A; 1 = Low risk; 2 = moderate risk; 3 = High risk
Referral: 0 = N/A; 1 = yes; 2 = no
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Referral ordered

Appendix D
Table D1
Demographic Frequencies of Patient, N = 84
N
Age
At most recent screening
At study visit
Mean time interval between
% of charts with at least partially
completed PARS
Gender
Male, %
Female, %
Race
White
Black
Other
Last Grade Completed
12
11
10
9
8
7
6
Unknown

%

23
61

27.4
72.6

44
28
12

52.4
33.3
14.3

21
14
15
12
2
5
1
14

25.0
16.7
17.9
14.3
2.4
6.0
1.2
16.7

Lives with
One Parent
Two Parent
Grandparent
Other Family Member
Unknown

35
26
5
2
2

41.7
31.0
6.0
2.4
2.4

Past MH Treatment
Males—Yes
Males—No
Females—Yes
Females—No

6
17
22
38

7.1
20.2
26.2
45.2

Referral at Time of Screen
Yes
No

18
66

21.4
78.6

72

Mean

SD

15.00
17.00
2.00

1.7
1.7
1.2

1.73

0.45

1.55

0.68

8.58

4.1

2.14

1.47

1.64

0.52

1.80

0.41

Table D2
PARS Risk Behavior Domains Completion (assessed for low, moderate, or high risk)*

% Complete
Tobacco Use

%/N
100% / 77

Drug Use

99% / 76

Alcohol Use

95% / 73

Abuse

95% / 73

School

94% / 72

Safety

94% / 72

Violence

94% / 72

Family Relations/Responsibility

94% / 72

Sexual Activity

91% / 70

Depression

91% / 70

Friends and Recreation

91% / 70

Nutrition

88% / 68

Exercise

88% / 68

BMI

78% / 60

Weight Perception

75% / 58

Good Qualities and Future Plans

74% / 57

Immunizations

47% / 36

*Less the seven charts without a PARS
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Table D3
Variables and Association With PARS Performed and/or Referral Made
Screened
Yes
No
Gender
Male
Female
Lives With
1 Parent
2 Parent
Other
Race
Caucasian
African American
Other

22
55

1
6

31
24
21

4
2
0

40
26
8

4
2
0

Sig (p < .05)
FET .668

Referral
Yes
No
2
15

21
45

8
5
4

27
20
17

10
5
0

33
23
8

Sig (p < .05)
FET .133

.281

.934

.666

.300

Table D4
Risk Behavior Domain Counts
______________________________________________________________________________
PARS Item
Low
Moderate
High
Total
______________________________________________________________________________
n
%
n
%
n
%
BMI
Males
Females
Weight Perception
Males
Females
Nutrition
Males
Females
Exercise
Males
Females
Tobacco use
Males
Females
Drug use
Males

34
10
24
48
14
34
40
12
28
19
7
12
69
20
49
64
19

57a
83
59
28
90
84

74

10
3
7
5
2
3
17
4
13
27
7
20
7
2
5
9
1

17
8
25
40
9
12

16
6
10
5
0
5
11
5
6
22
6
16
1
0
1
3
2

27

60

8

58

16

68

32

68

1

77

4

76

Females
Alcohol use
Males
Females
Sexual Activity
Males
Females
School
Males
Females
Depression
Males
Females
Abuse
Males
Females
Safety
Males
Females
Violence
Males
Females
Family relationships
Males
Females
Friends/recreation
Males
Females
Good qualities/future plans
Males
Females

45
60
18
42
51
17
34
55
14
41
48
14
34
61
17
44
66
18
48
68
18
50
61
19
42
60
18
42
50
14
36

82
73
76
69
84
92
94
85
86
88

8
11
2
9
11
4
7
12
3
9
14
4
10
11
3
8
6
2
4
2
1
1
7
1
6
9
1
8
4
1
3

15
16
17
20
15
8
3
9
13
7

1
2
0
2
8
0
8
5
3
2
8
3
5
1
0
1
0
0
0
2
2
0
4
1
3
1
1
0
3
2
1

3

73

11

70

7

72

11

70

1

73

0

72

3

72

6

72

1

70

5

57

*Immunization Domain on PARS not included as the focus was on adolescent behaviors.
**Figures based upon review of 84 medical records.
a Percentages may not be 100% accurate due to rounding; percentage was calculated based upon completed domains.
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